Full-Time
Confirmed live in the last 24 hours
Develops treatments for neurodegenerative diseases
Senior, Expert
No H1B Sponsorship
Cambridge, MA, USA
Must reside and work within the United States, in a state where Amylyx currently does business. Required to travel to the corporate location in Cambridge, MA several times a year.
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.
Company Size
51-200
Company Stage
IPO
Total Funding
$166.7M
Headquarters
Cambridge, Massachusetts
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Lahar Mehta, M.D. Lahar Mehta, M.D., joins Nura Bio from Amylyx Pharmaceuticals, where he was Senior Vice President/Head, Global Clinical Development, leading clinical development and clinical pharmacology activities across several indications including amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and Wolfram syndrome.
On January 10, 2025, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced its entry into an underwriting agreement with Leerink Partners LLC for the issuance and sale of 17,142,857 shares of its common stock at a price of $3.50 per share.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 s
Amylyx Pharmaceuticals appoints Dan Monahan as Chief Commercial Officer.
Amylyx partners with Gubra for GLP-1 antagonist.